New Integrase Inhibitors RAL, EVG and DTG improving the efficacy of ARVs in controlling HIV replication by providing personalized therapy.
Continue readingPosts Tagged → #HIVtreatment
New Integrase Inhibitors Better In Controlling HIV Replication than Other Antiretrovirals
Availability of new integrase inhibitors offers better opportunities to improve efficiency of cART and PEP in controlling HIV replication.
Continue readingHIV PEP drugs: Truvada® combination therapy
Truvada® is commonly used in combination with Isentress® for PEP due to the effectiveness and lack of negative interaction between the two drugs. Learn more in this detailed guide.
Continue readingHIV PEP drugs: Isentress® (Raltegravir) intergrase inhibitor
Isentress® is one of the newest classes of antiretrovirals, the intergrase inhibitors. This drug disables the HIV intergrase protein which is responsible for integrating the viral genome into the human chromosome and causing the chronic incurable infection. Developed by Merck and Co, it was approved for adult use in 2007 by the FDA and use… Continue reading
HIV PEP Drugs: Viread® (tenofovir) nucleotide analogue reverse transcriptase inhibitor (NRTI)
Tenofovir (Viread®) was invented by Antonín Holý from at the Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic and patented in 1984, making this one of the earliest antiviral drugs. In collaboration with Gilead Sciences and the University of California, it was developed into its current form and was approved for… Continue reading
HIV PEP drugs: Emtriva® (emtricitabine) reverse transcriptase inhibitor
Emtricitabine was developed as a combined effort between Dr. Dennis C. Liotta, Dr. Raymond F. Schinazi, and Dr. Woo-Baeg Choi at Emory university and was patented by Emory through Triangle Pharmaceuticals under the trade name of Emtriva® in 1996. Triangle Pharmaceuticals has been owned by Gilead Sciences since 2003. Emtriva®™ targets the HIV protein reverse transcriptase. By inhibiting… Continue reading
HIV PEP drugs: Kaletra® (lopinavir/ritonavir) viral protease inhibitors
The HIV PEP designer drug Kaletra® (LPV/r) contains the two HIV viral protease inhibitors lopinavir (LPV) and ritonavir (RTV) [Norvir®]. Developed by Abbott laboratories in 2000, it is referred to as a designer drug as it was specifically formulated based on X-ray crystallography structures to specifically target the HIV protease. Both lopinavir and ritonavir inhibit the… Continue reading
The World of Antiretrovirals
In the 1980’s diagnosis with HIV was a death sentence. In 1995 in the USA, it was the highest cause of death in the age range 25-44 years. Nowadays HIV is a life sentence, but a relatively painless one. Anti-retroviral therapy (ART) has ensured that the virus is kept locked away in the host DNA,… Continue reading
New York State Department of Health AIDS Institute recently updated their HIV PEP guidelines
The New York State Department of Health AIDS Institute (NYSDHAI) recently tasked their Medical Care Criteria Committee (MCCC) to update their HIV PEP (Post-exposure Prophylaxis) guidelines. PEP refers to the treatment required and administered after exposure to HIV – a sexually transmitted disease (STD). This exposure is categorised as resulting from sexual assault, occupational exposure,… Continue reading